Beth Chasen

1.4k total citations · 1 hit paper
19 papers, 557 citations indexed

About

Beth Chasen is a scholar working on Neurology, Epidemiology and Oncology. According to data from OpenAlex, Beth Chasen has authored 19 papers receiving a total of 557 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Neurology, 12 papers in Epidemiology and 9 papers in Oncology. Recurrent topics in Beth Chasen's work include Neuroblastoma Research and Treatments (13 papers), Neuroendocrine Tumor Research Advances (11 papers) and Lung Cancer Research Studies (7 papers). Beth Chasen is often cited by papers focused on Neuroblastoma Research and Treatments (13 papers), Neuroendocrine Tumor Research Advances (11 papers) and Lung Cancer Research Studies (7 papers). Beth Chasen collaborates with scholars based in United States, Germany and Sweden. Beth Chasen's co-authors include David Bushnell, Philippe Ruszniewski, Timothy J. Hobday, Edward M. Wolin, Maribel Lopera Sierra, Matthew H. Kulke, Andrew Hendifar, Richard P. Baum, Jonathan Strosberg and Kjell Öberg and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer.

In The Last Decade

Beth Chasen

19 papers receiving 552 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Health-Related Quality of Life in Patients With Progressive Midgut Neuroendocrine Tumors Treated With ¹⁷⁷Lu-Dotatate in the Phase III NETTER-1 Trial

2018 272 citations Jonathan Strosberg, Edward M. Wolin et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Beth Chasen United States	11	369	343	261	122	78	19	557
M. Caracciolo Italy	5	239 0.6×	274 0.8×	131 0.5×	106 0.9×	157 2.0×	5	572
Yi‐Zarn Wang United States	16	387 1.0×	364 1.1×	278 1.1×	23 0.2×	66 0.8×	47	567
Marianne E. Pavel Germany	5	564 1.5×	470 1.4×	369 1.4×	256 2.1×	29 0.4×	11	748
Wouter T. Zandee Netherlands	15	678 1.8×	626 1.8×	512 2.0×	34 0.3×	104 1.3×	38	836
Maria Rinzivillo Italy	20	990 2.7×	961 2.8×	600 2.3×	75 0.6×	77 1.0×	66	1.1k
Leilei Yuan China	12	134 0.4×	153 0.4×	94 0.4×	105 0.9×	93 1.2×	33	493
Beth Chasen United States	13	219 0.6×	297 0.9×	142 0.5×	164 1.3×	51 0.7×	35	576
C. Rodríguez Rodríguez Spain	8	118 0.3×	464 1.4×	61 0.2×	99 0.8×	56 0.7×	15	641
Luigi Bortolotti Italy	14	187 0.5×	118 0.3×	273 1.0×	140 1.1×	209 2.7×	29	871
Phillip G. Claringbold Australia	10	528 1.4×	536 1.6×	427 1.6×	200 1.6×	49 0.6×	12	695

Countries citing papers authored by Beth Chasen

Since Specialization

Citations

This map shows the geographic impact of Beth Chasen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Beth Chasen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Beth Chasen more than expected).

Fields of papers citing papers by Beth Chasen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Beth Chasen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Beth Chasen. The network helps show where Beth Chasen may publish in the future.

Co-authorship network of co-authors of Beth Chasen

This figure shows the co-authorship network connecting the top 25 collaborators of Beth Chasen. A scholar is included among the top collaborators of Beth Chasen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Beth Chasen. Beth Chasen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

Puebla‐Osorio, Nahum, Robin Michelet, Michael R. Green, et al.. (2021). Early Survival Prediction Framework in CD19-Specific CAR-T Cell Immunotherapy Using a Quantitative Systems Pharmacology Model. Cancers. 13(11). 2782–2782. 30 indexed citations

Kaseb, Ahmed O., S. Cheenu Kappadath, Sunyoung S. Lee, et al.. (2021). A Prospective Phase II Study of Safety and Efficacy of Sorafenib Followed by 90Y Glass Microspheres for Patients with Advanced or Metastatic Hepatocellular Carcinoma. SHILAP Revista de lepidopterología. Volume 8. 1129–1145. 10 indexed citations

Jp, Long, et al.. (2020). Survival Outcomes for Yttrium-90 Transarterial Radioembolization With and Without Sorafenib for Unresectable Hepatocellular Carcinoma Patients. SHILAP Revista de lepidopterología. 1 indexed citations

Chasen, Beth, William D. Erwin, Nicole D. Fleming, et al.. (2019). Preoperative PET/CT does not accurately detect extrauterine disease in patients with newly diagnosed high‐risk endometrial cancer: A prospective study. Cancer. 125(19). 3347–3353. 14 indexed citations

Jiménez, Camilo, William D. Erwin, & Beth Chasen. (2019). Targeted Radionuclide Therapy for Patients with Metastatic Pheochromocytoma and Paraganglioma: From Low-Specific-Activity to High-Specific-Activity Iodine-131 Metaiodobenzylguanidine. Cancers. 11(7). 1018–1018. 55 indexed citations

Strosberg, Jonathan, Edward M. Wolin, Beth Chasen, et al.. (2018). QOL Improvements in NETTER-1 Phase III Trial in Patients With Progressive Midgut Neuroendocrine Tumors. Pancreas. 47(3). 355–355. 3 indexed citations

Feghali, Karine A. Al, et al.. (2018). The Use of 68Ga-DOTATATE PET/CT in the Non-invasive Diagnosis of Optic Nerve Sheath Meningioma: A Case Report. Frontiers in Oncology. 8. 454–454. 15 indexed citations

Chasen, Beth, William D. Erwin, Nicole D. Fleming, et al.. (2018). The utility of preoperative PET/CT in the detection of extrauterine disease in high-risk endometrial cancer: A prospective study. Gynecologic Oncology. 149. 32–32. 1 indexed citations

Strosberg, Jonathan, Edward M. Wolin, Beth Chasen, et al.. (2018). Health-Related Quality of Life in Patients With Progressive Midgut Neuroendocrine Tumors Treated With ¹⁷⁷Lu-Dotatate in the Phase III NETTER-1 Trial. Journal of Clinical Oncology. 36(25). 2578–2584. 272 indexed citations breakdown →

10.

Wolin, Edward M., Beth Chasen, M. Kulke, et al.. (2017). NETTER-1 Phase III Trial : Recent Findings on Quality of Life in Patients with Midgut Neuroendocrine Tumors. Neuroendocrinology. 105. 257–257. 2 indexed citations

11.

Wolin, Edward M., Beth Chasen, Matthew H. Kulke, et al.. (2017). Improved time to quality of life deterioration in patients with progressive midgut neuroendocrine tumors treated with 177Lu-DOTATATE: The NETTER-1 phase III trial. Annals of Oncology. 28. v146–v146. 4 indexed citations

12.

Strosberg, Jonathan, Edward M. Wolin, Beth Chasen, et al.. (2017). Quality-of-life findings in patients with midgut neuroendocrine tumors: Results of the NETTER-1 phase III trial.. Journal of Clinical Oncology. 35(4_suppl). 348–348. 3 indexed citations

13.

Lee, Jeff, et al.. (2016). Cross sectional and nuclear medicine imaging of pancreatic insulinomas. Abdominal Radiology. 42(2). 531–543. 10 indexed citations

14.

Strosberg, Jonathan, Edward M. Wolin, Beth Chasen, et al.. (2016). NETTER-1 Phase III in Patients With Midgut Neuroendocrine Tumors Treated With 177Lu-DOTATATE: Efficacy and Safety Results.. Neuroendocrinology. 103(5 Suppl 7). 629–629. 19 indexed citations

15.

Strosberg, Jonathan, Edward M. Wolin, Beth Chasen, et al.. (2016). O-009 NETTER-1 phase III: efficacy and safety results in patients with midgut neuroendocrine tumors treated with 177Lu-dotatate. Annals of Oncology. 27. ii121–ii121. 2 indexed citations

16.

Strosberg, Jonathan, Edward M. Wolin, Beth Chasen, et al.. (2016). NETTER-1 phase III: Progression-free survival, radiographic response, and preliminary overall survival results in patients with midgut neuroendocrine tumors treated with 177-Lu-Dotatate.. Journal of Clinical Oncology. 34(4_suppl). 194–194. 45 indexed citations

17.

Strosberg, Jonathan, Edward M. Wolin, Beth Chasen, et al.. (2016). NETTER-1 Phase III in Patients with Midgut Neuroendocrine Tumors Treated with 177Lu-Dotatate: Efficacy, Safety, QoL Results and Subgroup Analysis. Endocrine Abstracts. 4 indexed citations

18.

Wolin, Edward M., Beth Chasen, Michael Kulke, et al.. (2015). 6LBA 177-Lu-Dotatate significantly improves progression-free survival in patients with midgut neuroendocrine tumours: Results of the phase III NETTER-1 trial. European Journal of Cancer. 51. S710–S710. 38 indexed citations

19.

Haygood, Tamara Miner, et al.. (2011). Migration of central lines from the superior vena cava to the azygous vein. Clinical Radiology. 67(1). 49–54. 29 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact